Bibi Shabana, Mir Sadullah, Rehman Wajid, Menaa Farid, Gul Alia, Alaryani Fatima Saad Salem, Alqahtani Ali M, Haq Sirajul, Abdellatif Magda H
Department of Chemistry, Hazara University, Mansehra 21220, Pakistan.
Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Islamabad 22060, Pakistan.
Materials (Basel). 2022 May 30;15(11):3885. doi: 10.3390/ma15113885.
(1) Background: Nanocomposite films are widely applied in the pharmaceutical industry (e.g., nanodrug delivery systems-NDDS). Indeed, these nanomaterials can be produced at a large industrial scale and display valuable properties (e.g., antibacterial, renewability, biodegradability, bioavailability, safety, tissue-specific targeting, and biocompatibility), which can enhance the activity of conventional marketed drugs. (2) Aim: To fabricate and investigate the in vitro properties of the antibiotic ceftriaxone sodium (CTX) once encapsulated into sodium alginate (SA)/poly(vinyl alcohol)PVA-clay reinforced nanocomposite films. (3) Methods: Different ratios of the polymers (i.e., SA, PVA) and CTX drug were used for the synthesis of nanocomposite films by solvent casting technique. Montmorillonite (MMT), modified organically, was added as a nanofiller to increase their thermal and mechanical strength. The prepared samples were physically characterized by thermogravimetric analysis (TGA), X-ray diffraction (XRD), scanning electronic microscopy (SEM), and energy-dispersive X-ray analysis (EDX). The physicochemical behavior (i.e., swelling, erosion, dissolution/drug release behavior and rat skin permeation) was also assessed. Comparisons were made with the currently marketed free CTX dosage form. (4) Results: TGA of the nanoformulation showed increased thermostability. XRD revealed its semi-crystalline nature. SEM depicted a homogeneous drug-loaded SA/PVA nanocomposite with an average size ranging between 300 and 500 nm. EDX confirmed the elemental composition and uniform distribution of mixing components. The water entrapment efficiency study showed that the highest swelling and erosion ratio is encountered with the nanoformulations S100(3) and S100D15(3). Ex vivo permeation revealed a bi-step discharge mode with an early burst liberation chased by continued drug discharge of devised nanoparticles (NPs). The dissolution studies of the drug-loaded polymer nanocomposites elicited sustained pH-dependent drug release. The cumulative drug release was the highest (90.93%) with S100D15(3). (5) Conclusion: S100D15(3) was the finest formulation. To the best of our knowledge, we also pioneered the use of solvent casting for the preparation of such nanoformulations. Polymers and reinforcing agent, concentrations and pH were rate-deterring features for the preparation of the optimized formulation. Thus, CTX-loaded SA/PVA-MMT reinforced nanocomposite appeared as a promising nanodrug delivery system (NDDS) based on its in vitro physicochemical properties.
(1) 背景:纳米复合膜在制药行业中得到广泛应用(例如,纳米药物递送系统 - NDDS)。实际上,这些纳米材料能够大规模工业化生产,并具有宝贵的特性(如抗菌性、可再生性、生物可降解性、生物利用度、安全性、组织特异性靶向性和生物相容性),这些特性可增强传统市售药物的活性。(2) 目的:制备并研究抗生素头孢曲松钠(CTX)一旦包封于海藻酸钠(SA)/聚乙烯醇(PVA) - 粘土增强纳米复合膜后的体外性质。(3) 方法:采用溶剂浇铸技术,使用不同比例的聚合物(即SA、PVA)和CTX药物合成纳米复合膜。添加有机改性的蒙脱石(MMT)作为纳米填料以提高其热稳定性和机械强度。通过热重分析(TGA)、X射线衍射(XRD)、扫描电子显微镜(SEM)和能量色散X射线分析(EDX)对制备的样品进行物理表征。还评估了其物理化学行为(即溶胀、侵蚀、溶解/药物释放行为和大鼠皮肤渗透)。与目前市售的游离CTX剂型进行比较。(4) 结果:纳米制剂的TGA显示热稳定性提高。XRD揭示了其半结晶性质。SEM描绘了一种均匀的载药SA/PVA纳米复合材料,平均尺寸在300至500纳米之间。EDX证实了混合成分的元素组成和均匀分布。水包封效率研究表明,纳米制剂S100(3)和S100D15(3)的溶胀和侵蚀率最高。体外渗透显示出双步释放模式,即设计的纳米颗粒(NPs)在早期爆发释放后持续药物释放。载药聚合物纳米复合材料的溶解研究引发了持续的pH依赖性药物释放。S100D15(3)的累积药物释放最高(90.93%)。(5) 结论:S100D15(3)是最佳制剂。据我们所知,我们还率先使用溶剂浇铸法制备此类纳米制剂。聚合物、增强剂、浓度和pH是制备优化制剂的限速因素。因此,基于其体外物理化学性质,载CTX的SA/PVA - MMT增强纳米复合材料似乎是一种有前途的纳米药物递送系统(NDDS)。